124 related articles for article (PubMed ID: 36584810)
21. Six-Year Evaluation of Same-Day Discharge following Conventional Transarterial Chemoembolization of Hepatocellular Carcinoma.
Hund HC; Frantz SK; Wu H; Adeniran OR; Wong TY; Borgmann AJ; Matsuoka L; Geevarghese S; Alexopoulos S; Shingina A; Meranze SG; Baker JC; Garbett S; Brown DB
J Vasc Interv Radiol; 2023 Mar; 34(3):378-385. PubMed ID: 36481322
[TBL] [Abstract][Full Text] [Related]
22. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.
Aramaki O; Takayama T; Moriguchi M; Sakamoto H; Yodono H; Kokudo N; Yamanaka N; Kawasaki S; Sasaki Y; Kubota K; Otsuji E; Tanaka S; Matsuyama Y; Fujii M;
Eur J Cancer; 2021 Nov; 157():373-382. PubMed ID: 34563992
[TBL] [Abstract][Full Text] [Related]
23. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents.
Chen S; Yu W; Zhang K; Liu W; Chen Q
Medicine (Baltimore); 2018 May; 97(21):e10832. PubMed ID: 29794774
[TBL] [Abstract][Full Text] [Related]
24. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
Yodono H; Matsuo K; Shinohara A
Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
[TBL] [Abstract][Full Text] [Related]
25. Balloon-occluded transarterial chemoembolization using a 1.8-French tip coaxial microballoon catheter for hepatocellular carcinoma: technical and safety considerations.
Matsumoto T; Endo J; Hashida K; Ichikawa H; Kojima S; Takashimizu S; Watanabe N; Yamagami T; Hasebe T
Minim Invasive Ther Allied Technol; 2015 Apr; 24(2):94-100. PubMed ID: 25263680
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
[TBL] [Abstract][Full Text] [Related]
27. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Li JJ; Zheng JS; Cui SC; Cui XW; Hu CX; Fang D; Ye LC
World J Gastroenterol; 2015 Mar; 21(10):3035-40. PubMed ID: 25780303
[TBL] [Abstract][Full Text] [Related]
28. Peritumoral portal enhancement during transarterial chemoembolization: a potential prognostic factor for patients with hepatocellular carcinoma.
Nyman SS; Creusen AD; Johnsson U; Rorsman F; Vessby J; Barbier CE
Acta Radiol; 2022 Oct; 63(10):1323-1331. PubMed ID: 34665054
[TBL] [Abstract][Full Text] [Related]
29. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
Seki A; Hori S
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):555-62. PubMed ID: 21562932
[TBL] [Abstract][Full Text] [Related]
30. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.
Yu SC; Hui JW; Hui EP; Chan SL; Lee KF; Mo F; Wong J; Ma B; Lai P; Mok T; Yeo W
Radiology; 2014 Feb; 270(2):607-20. PubMed ID: 24126369
[TBL] [Abstract][Full Text] [Related]
31. Transarterial embolization/chemoembolization therapy for hepatocellular carcinoma fed by adrenal artery: Preliminary results.
Hu S; Tu J; Jia Z; Huang Y; Jiang G
Medicine (Baltimore); 2016 Dec; 95(52):e5762. PubMed ID: 28033293
[TBL] [Abstract][Full Text] [Related]
32. Transarterial chemoembolization for hepatocellular carcinoma: significance of extrahepatic collateral supply.
Paul SB; Gamanagatti SR; Mukund A; Abbas SZ; Acharya SK
Indian J Cancer; 2011; 48(3):339-44. PubMed ID: 21921335
[TBL] [Abstract][Full Text] [Related]
33. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
34. TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma.
Huang D; Chen Y; Chen S; Zeng Q; Zhao J; Wu R; Li Y
Medicine (Baltimore); 2017 Jul; 96(30):e7650. PubMed ID: 28746230
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
36. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
[TBL] [Abstract][Full Text] [Related]
37. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.
Guiu B; Deschamps F; Aho S; Munck F; Dromain C; Boige V; Malka D; Leboulleux S; Ducreux M; Schlumberger M; Baudin E; de Baere T
J Hepatol; 2012 Mar; 56(3):609-17. PubMed ID: 22027582
[TBL] [Abstract][Full Text] [Related]
38. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
39. Liver stiffness measurement changes following hepatocellular carcinoma treatment with percutaneous microwave ablation or transarterial chemoembolization: a cohort study.
Abdelaziz AO; Abdelhalim H; Elsharkawy A; Shousha HI; Abdelmaksoud AH; Soliman ZA; Seif MI; Sayed DB; Farouk MH; Elbaz TM; Nabeel MM
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):685-691. PubMed ID: 30640743
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
